S. Birtles

发表

Proopiomelanocortin-derived peptides in rat cerebrospinal fluid and hypothalamic extracts: evidence that secretion is regulated with respect to energy balance.

A. Turnbull, C. Lawrence, L. E. Pritchard, 2003, Endocrinology.

Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).

Magnus J. Johansson, Tobias Noeske, Robert D. M. Davies, 2012, Journal of medicinal chemistry.

Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol

J. Yates, C. Nilsson, S. Birtles, 2019, Pharmacology research & perspectives.

Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats.

S. Boyer, A. Turnbull, D. Masters, 2002, Diabetes.

Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice

D. Smith, A. Turnbull, J. R. Arch, 2006, Diabetologia.

Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.

A. Turnbull, P. Kemmitt, A. Birch, 2009, Journal of medicinal chemistry.

Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying

W. Blaner, I. Goldberg, A. Turnbull, 2012, Journal of Lipid Research.

Intestinal DGAT 1 defi ciency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying Gene

W. Blaner, I. Goldberg, A. Turnbull, 2012 .

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.

Andrew G. Leach, A. Plowright, Robert D. M. Davies, 2012, Bioorganic & medicinal chemistry letters.

Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats[S]

W. Langhans, A. Turnbull, G. Pacheco-López, 2013, Journal of Lipid Research.

DGAT-1 inhibition increases plasma glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) levels in response to a high fat (HF) meal in rats

W. Langhans, A. Turnbull, M. Arnold, 2011, Appetite.

Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1 – the discovery of AZD2353

Andrew G. Leach, M. Waring, P. Macfaul, 2013 .

Design and synthesis of a novel series of cyclohexyloxy-pyridyl derivatives as inhibitors of diacylglycerol acyl transferase 1

Andrew G. Leach, A. Plowright, M. Waring, 2013 .

Discovery and optimization of efficacious neutral 4-amino-6-biphenyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one diacylglycerol acyl transferase-1 (DGAT1) inhibitors

A. Leach, Wendy L. Snelson, A. Birch, 2013 .

Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).

Magnus J. Johansson, Tobias Noeske, Robert D. M. Davies, 2012, Journal of medicinal chemistry.